{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:52:14Z","timestamp":1770511934534,"version":"3.49.0"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"13","license":[{"start":{"date-parts":[[2014,8,26]],"date-time":"2014-08-26T00:00:00Z","timestamp":1409011200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2014,9]]},"DOI":"10.1007\/s40265-014-0281-x","type":"journal-article","created":{"date-parts":[[2014,8,25]],"date-time":"2014-08-25T08:53:46Z","timestamp":1408956826000},"page":"1457-1465","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":26,"title":["Rosacea: New and Emerging Treatments"],"prefix":"10.1007","volume":"74","author":[{"given":"Farah A.","family":"Moustafa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura F.","family":"Sandoval","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven R.","family":"Feldman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2014,8,26]]},"reference":[{"issue":"6 Suppl 1","key":"281_CR1","doi-asserted-by":"crossref","first-page":"S27","DOI":"10.1016\/j.jaad.2013.04.043","volume":"69","author":"J Tan","year":"2013","unstructured":"Tan J, Berg M. Rosacea: current state of epidemiology. J Am Acad Dermatol. 2013;69(6 Suppl 1):S27\u201335.","journal-title":"J Am Acad Dermatol"},{"key":"281_CR2","unstructured":"National Rosacea Society. If you have rosacea, you\u2019re not alone. 2014. http:\/\/www.rosacea.org\/patients\/index.php . Accessed 28 Apr 2014."},{"issue":"4","key":"281_CR3","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1067\/mjd.2002.120625","volume":"46","author":"J Wilkin","year":"2002","unstructured":"Wilkin J, Dahl M, Detmar M, Drake L, Feinstein A, Odom R, et al. Standard classification of rosacea: report of the National Rosacea Society Expert Committee on the classification and staging of rosacea. J Am Acad Dermatol. 2002;46(4):584\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"281_CR4","first-page":"385","volume":"65","author":"M Salamon","year":"2008","unstructured":"Salamon M, Chodkiewicz J, Sysa-Jedrzejowska A, Wozniacka A. Quality of life in patients with rosacea [in Polish]. Przegl Lek. 2008;65(9):385\u20139.","journal-title":"Przegl Lek"},{"issue":"2","key":"281_CR5","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1111\/j.1468-3083.2010.03751.x","volume":"25","author":"BE Elewski","year":"2011","unstructured":"Elewski BE, Draelos Z, Dreno B, Jansen T, Layton A, Picardo M. Rosacea\u2014global diversity and optimized outcome: proposed international consensus from the Rosacea International Expert Group. J Eur Acad Dermatol Venereol. 2011;25(2):188\u2013200.","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"6 Suppl 1","key":"281_CR6","doi-asserted-by":"crossref","first-page":"S15","DOI":"10.1016\/j.jaad.2013.04.045","volume":"69","author":"M Steinhoff","year":"2013","unstructured":"Steinhoff M, Schauber J, Leyden JJ. New insights into rosacea pathophysiology: a review of recent findings. J Am Acad Dermatol. 2013;69(6 Suppl 1):S15\u201326.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"281_CR7","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1038\/jidsymp.2011.7","volume":"15","author":"M Steinhoff","year":"2011","unstructured":"Steinhoff M, Buddenkotte J, Aubert J, Sulk M, Novak P, Schwab VD, et al. Clinical, cellular, and molecular aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15(1):2\u201311.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"8","key":"281_CR8","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1038\/nm1616","volume":"13","author":"K Yamasaki","year":"2007","unstructured":"Yamasaki K, Di NA, Bardan A, Murakami M, Ohtake T, Coda A, et al. Increased serine protease activity and cathelicidin promotes skin inflammation in rosacea. Nat Med. 2007;13(8):975\u201380.","journal-title":"Nat Med"},{"issue":"3","key":"281_CR9","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1038\/jid.2010.351","volume":"131","author":"K Yamasaki","year":"2011","unstructured":"Yamasaki K, Kanada K, Macleod DT, Borkowski AW, Morizane S, Nakatsuji T, et al. TLR2 expression is increased in rosacea and stimulates enhanced serine protease production by keratinocytes. J Invest Dermatol. 2011;131(3):688\u201397.","journal-title":"J Invest Dermatol"},{"issue":"3","key":"281_CR10","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2004.03.030","volume":"51","author":"GH Crawford","year":"2004","unstructured":"Crawford GH, Pelle MT, James WD. Rosacea: I. Etiology, pathogenesis, and subtype classification. J Am Acad Dermatol. 2004;51(3):327\u201341.","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"281_CR11","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/0190-9622(92)70086-U","volume":"26","author":"S Sibenge","year":"1992","unstructured":"Sibenge S, Gawkrodger DJ. Rosacea: a study of clinical patterns, blood flow, and the role of Demodex folliculorum. J Am Acad Dermatol. 1992;26(4):590\u20133.","journal-title":"J Am Acad Dermatol"},{"issue":"5","key":"281_CR12","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaad.2007.06.009","volume":"57","author":"DA Guzman-Sanchez","year":"2007","unstructured":"Guzman-Sanchez DA, Ishiuji Y, Patel T, Fountain J, Chan YH, Yosipovitch G. Enhanced skin blood flow and sensitivity to noxious heat stimuli in papulopustular rosacea. J Am Acad Dermatol. 2007;57(5):800\u20135.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"281_CR13","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jdermsci.2009.04.007","volume":"55","author":"K Yamasaki","year":"2009","unstructured":"Yamasaki K, Gallo RL. The molecular pathology of rosacea. J Dermatol Sci. 2009;55(2):77\u201381.","journal-title":"J Dermatol Sci"},{"issue":"5","key":"281_CR14","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1111\/j.1346-8138.2010.00999.x","volume":"38","author":"JH Kim","year":"2011","unstructured":"Kim JH, Oh YS, Ji JH, Bak H, Ahn SK. Rosacea (erythematotelangiectatic type) effectively improved by topical xylometazoline. J Dermatol. 2011;38(5):510\u20133.","journal-title":"J Dermatol"},{"issue":"3","key":"281_CR15","first-page":"26","volume":"5","author":"JQ Rosso Del","year":"2012","unstructured":"Del Rosso JQ. Advances in understanding and managing rosacea: part 2: the central role, evaluation, and medical management of diffuse and persistent facial erythema of rosacea. J Clin Aesthet Dermatol. 2012;5(3):26\u201336.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"6 Suppl 1","key":"281_CR16","doi-asserted-by":"crossref","first-page":"S44","DOI":"10.1016\/j.jaad.2013.06.009","volume":"69","author":"JQ Rosso Del","year":"2013","unstructured":"Del Rosso JQ. Management of facial erythema of rosacea: what is the role of topical alpha-adrenergic receptor agonist therapy? J Am Acad Dermatol. 2013;69(6 Suppl 1):S44\u201356.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"281_CR17","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1038\/jidsymp.2011.6","volume":"15","author":"VD Schwab","year":"2011","unstructured":"Schwab VD, Sulk M, Seeliger S, Nowak P, Aubert J, Mess C, et al. Neurovascular and neuroimmune aspects in the pathophysiology of rosacea. J Investig Dermatol Symp Proc. 2011;15(1):53\u201362.","journal-title":"J Investig Dermatol Symp Proc"},{"issue":"11","key":"281_CR18","doi-asserted-by":"crossref","first-page":"1369","DOI":"10.1001\/archderm.143.11.1369","volume":"143","author":"SD Shanler","year":"2007","unstructured":"Shanler SD, Ondo AL. Successful treatment of the erythema and flushing of rosacea using a topically applied selective alpha1-adrenergic receptor agonist, oxymetazoline. Arch Dermatol. 2007;143(11):1369\u201371.","journal-title":"Arch Dermatol"},{"issue":"6","key":"281_CR19","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/j.1365-2133.1993.tb00261.x","volume":"128","author":"F Forton","year":"1993","unstructured":"Forton F, Seys B. Density of Demodex folliculorum in rosacea: a case-control study using standardized skin-surface biopsy. Br J Dermatol. 1993;128(6):650\u20139.","journal-title":"Br J Dermatol"},{"issue":"5 Pt 1","key":"281_CR20","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/S0190-9622(99)70022-8","volume":"41","author":"C Forstinger","year":"1999","unstructured":"Forstinger C, Kittler H, Binder M. Treatment of rosacea-like demodicidosis with oral ivermectin and topical permethrin cream. J Am Acad Dermatol. 1999;41(5 Pt 1):775\u20137.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"281_CR21","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1001\/jamadermatol.2013.7688","volume":"150","author":"M Brown","year":"2014","unstructured":"Brown M, Hernandez-Martin A, Clement A, Colmenero I, Torrelo A. Severe demodexfolliculorum-associated oculocutaneous rosacea in a girl successfully treated with ivermectin. JAMA Dermatol. 2014;150(1):61\u20133.","journal-title":"JAMA Dermatol"},{"issue":"1","key":"281_CR22","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.jaad.2004.05.034","volume":"52","author":"F Forton","year":"2005","unstructured":"Forton F, Germaux MA, Brasseur T, De LA, Laporte M, Mathys C, et al. Demodicosis and rosacea: epidemiology and significance in daily dermatologic practice. J Am Acad Dermatol. 2005;52(1):74\u201387.","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"281_CR23","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1111\/j.1365-2133.2007.08028.x","volume":"157","author":"N Lacey","year":"2007","unstructured":"Lacey N, Delaney S, Kavanagh K, Powell FC. Mite-related bacterial antigens stimulate inflammatory cells in rosacea. Br J Dermatol. 2007;157(3):474\u201381.","journal-title":"Br J Dermatol"},{"issue":"5","key":"281_CR24","first-page":"234","volume":"92","author":"JQ Rosso Del","year":"2013","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield L, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 1: a status report on the disease state, general measures, and adjunctive skin care. Cutis. 2013;92(5):234\u201340.","journal-title":"Cutis"},{"issue":"4","key":"281_CR25","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1111\/j.1365-2133.2011.10473.x","volume":"165","author":"EJ Zuuren van","year":"2011","unstructured":"van Zuuren EJ, Kramer SF, Carter BR, Graber MA, Fedorowicz Z. Effective and evidence-based management strategies for rosacea: summary of a Cochrane systematic review. Br J Dermatol. 2011;165(4):760\u201381.","journal-title":"Br J Dermatol"},{"issue":"2","key":"281_CR26","first-page":"71","volume":"93","author":"E Tanghetti","year":"2014","unstructured":"Tanghetti E, Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Eichenfield LF, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 4: a status report on physical modalities and devices. Cutis. 2014;93(2):71\u20136.","journal-title":"Cutis"},{"issue":"2","key":"281_CR27","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jaad.2005.10.004","volume":"54","author":"AN Sapadin","year":"2006","unstructured":"Sapadin AN, Fleischmajer R. Tetracyclines: nonantibiotic properties and their clinical implications. J Am Acad Dermatol. 2006;54(2):258\u201365.","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"281_CR28","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1016\/j.phrs.2010.10.007","volume":"63","author":"E Monk","year":"2011","unstructured":"Monk E, Shalita A, Siegel DM. Clinical applications of non-antimicrobial tetracyclines in dermatology. Pharmacol Res. 2011;63(2):130\u201345.","journal-title":"Pharmacol Res"},{"issue":"6","key":"281_CR29","first-page":"573","volume":"7","author":"JQ Rosso Del","year":"2008","unstructured":"Del Rosso JQ, Schlessinger J, Werschler P. Comparison of anti-inflammatory dose doxycycline versus doxycycline 100\u00a0mg in the treatment of rosacea. J Drugs Dermatol. 2008;7(6):573\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"5","key":"281_CR30","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1016\/j.jaad.2006.11.021","volume":"56","author":"JQ Rosso Del","year":"2007","unstructured":"Del Rosso JQ, Webster GF, Jackson M, Rendon M, Rich P, Torok H, et al. Two randomized phase III clinical trials evaluating anti-inflammatory dose doxycycline (40-mg doxycycline, USP capsules) administered once daily for treatment of rosacea. J Am Acad Dermatol. 2007;56(5):791\u2013802.","journal-title":"J Am Acad Dermatol"},{"issue":"9","key":"281_CR31","first-page":"54","volume":"4","author":"H Park","year":"2011","unstructured":"Park H, Del Rosso JQ. Use of oral isotretinoin in the management of rosacea. J Clin Aesthet Dermatol. 2011;4(9):54\u201361.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"1","key":"281_CR32","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/j.jdermsci.2014.04.002","volume":"75","author":"D Piwnica","year":"2014","unstructured":"Piwnica D, Rosignoli C, de Menonville ST, Alvarez T, Schuppli NM, Roye O, et al. Vasoconstriction and anti-inflammatory properties of the selective alpha-adrenergic receptor agonist brimonidine. J Dermatol Sci. 2014;75(1):49\u201354.","journal-title":"J Dermatol Sci"},{"issue":"3","key":"281_CR33","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1111\/j.1365-2133.2011.10716.x","volume":"166","author":"J Fowler","year":"2012","unstructured":"Fowler J, Jarratt M, Moore A, Meadows K, Pollack A, Steinhoff M, et al. Once-daily topical brimonidine tartrate gel 0.5\u00a0% is a novel treatment for moderate to severe facial erythema of rosacea: results of two multicentre, randomized and vehicle-controlled studies. Br J Dermatol. 2012;166(3):633\u201341.","journal-title":"Br J Dermatol"},{"issue":"6","key":"281_CR34","first-page":"650","volume":"12","author":"J Fowler Jr","year":"2013","unstructured":"Fowler J Jr, Jackson M, Moore A, Jarratt M, Jones T, Meadows K, et al. Efficacy and safety of once-daily topical brimonidine tartrate gel 0.5\u00a0% for the treatment of moderate to severe facial erythema of rosacea: results of two randomized, double-blind, and vehicle-controlled pivotal studies. J Drugs Dermatol. 2013;12(6):650\u20136.","journal-title":"J Drugs Dermatol"},{"issue":"2","key":"281_CR35","doi-asserted-by":"crossref","first-page":"e37","DOI":"10.1016\/j.jaad.2013.10.054","volume":"70","author":"ET Routt","year":"2014","unstructured":"Routt ET, Levitt JO. Rebound erythema and burning sensation from a new topical brimonidine tartrate gel 0.33\u00a0%. J Am Acad Dermatol. 2014;70(2):e37\u20138.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"281_CR36","first-page":"56","volume":"13","author":"A Moore","year":"2014","unstructured":"Moore A, Kempers S, Murakawa G, Weiss J, Tauscher A, Swinyer L, et al. Long-term safety and efficacy of once-daily topical brimonidine tartrate gel 0.5\u00a0% for the treatment of moderate to severe facial erythema of rosacea: results of a 1-year open-label study. J Drugs Dermatol. 2014;13(1):56\u201361.","journal-title":"J Drugs Dermatol"},{"key":"281_CR37","unstructured":"National Institutes of Health. Oxymetazoline drug information. 2014. http:\/\/dailymed.nlm.nih.gov\/dailymed\/search.cfm?startswith=oxymetazoline&x=0&y=0 . Accessed 28 Apr 2014."},{"issue":"1","key":"281_CR38","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1600-0773.1993.tb01955.x","volume":"73","author":"R Bjerknes","year":"1993","unstructured":"Bjerknes R, Steinsvag SK. Inhibition of human neutrophil actin polymerization, phagocytosis and oxidative burst by components of decongestive nosedrops. Pharmacol Toxicol. 1993;73(1):41\u20135.","journal-title":"Pharmacol Toxicol"},{"key":"281_CR39","unstructured":"Pascoe D. Allergan dose finding trials for AGN-199201 oxymetazoline. 2012. http:\/\/rosacea-support.org\/allergan-dose-finding-trials-for-agn-199201-oxymetazoline.html . Accessed 1 May 2014."},{"issue":"4","key":"281_CR40","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/j.1472-8206.2009.00684.x","volume":"23","author":"X Ci","year":"2009","unstructured":"Ci X, Li H, Yu Q, Zhang X, Yu L, Chen N, et al. Avermectin exerts anti-inflammatory effect by downregulating the nuclear transcription factor kappa-B and mitogen-activated protein kinase activation pathway. Fundam Clin Pharmacol. 2009;23(4):449\u201355.","journal-title":"Fundam Clin Pharmacol"},{"issue":"2","key":"281_CR41","first-page":"149","volume":"80","author":"KJ Allen","year":"2007","unstructured":"Allen KJ, Davis CL, Billings SD, Mousdicas N. Recalcitrant papulopustular rosacea in an immunocompetent patient responding to combination therapy with oral ivermectin and topical permethrin. Cutis. 2007;80(2):149\u201351.","journal-title":"Cutis"},{"issue":"9","key":"281_CR42","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1111\/j.1365-4632.2006.02924.x","volume":"45","author":"E Clyti","year":"2006","unstructured":"Clyti E, Nacher M, Sainte-Marie D, Pradinaud R, Couppie P. Ivermectin treatment of three cases of demodecidosis during human immunodeficiency virus infection. Int J Dermatol. 2006;45(9):1066\u20138.","journal-title":"Int J Dermatol"},{"issue":"3","key":"281_CR43","first-page":"316","volume":"13","author":"L Stein","year":"2014","unstructured":"Stein L, Kircik L, Fowler J, Tan J, Draelos Z, Fleischer A, et al. Efficacy and safety of ivermectin 1\u00a0% cream in treatment of papulopustular rosacea: results of two randomized, double-blind, vehicle-controlled pivotal studies. J Drugs Dermatol. 2014;13(3):316\u201323.","journal-title":"J Drugs Dermatol"},{"key":"281_CR44","unstructured":"Jancin B. Novel topical rosacea drug sails through phase III: expert analysis from SDEF Hawaii Dermatology Seminar. Skin and Allergy News. 2-19-2014. http:\/\/www.skinandallergynews.com\/index.php?id=372&cHash=071010&tx_ttnews[tt_news]=237841 . Accessed 20 Jul 2014."},{"issue":"1","key":"281_CR45","first-page":"20","volume":"2","author":"JB Bikowski","year":"2009","unstructured":"Bikowski JB, Del Rosso JQ. Demodex dermatitis: a retrospective analysis of clinical diagnosis and successful treatment with topical crotamiton. J Clin Aesthet Dermatol. 2009;2(1):20\u20135.","journal-title":"J Clin Aesthet Dermatol"},{"issue":"6","key":"281_CR46","first-page":"277","volume":"92","author":"JQ Rosso Del","year":"2013","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield L, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 2: a status report on topical agents. Cutis. 2013;92(6):277\u201384.","journal-title":"Cutis"},{"issue":"1","key":"281_CR47","first-page":"18","volume":"93","author":"JQ Rosso Del","year":"2014","unstructured":"Del Rosso JQ, Thiboutot D, Gallo R, Webster G, Tanghetti E, Eichenfield LF, et al. Consensus recommendations from the American Acne & Rosacea Society on the management of rosacea, part 3: a status report on systemic therapies. Cutis. 2014;93(1):18\u201328.","journal-title":"Cutis"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0281-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40265-014-0281-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-014-0281-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,6,2]],"date-time":"2019-06-02T19:41:38Z","timestamp":1559504498000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40265-014-0281-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,8,26]]},"references-count":47,"journal-issue":{"issue":"13","published-print":{"date-parts":[[2014,9]]}},"alternative-id":["281"],"URL":"https:\/\/doi.org\/10.1007\/s40265-014-0281-x","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,8,26]]}}}